Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (002864.SZ)
CNY 31.99
(1.62%)
CNY 31.99
(1.62%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 980.82 Million | 974.29 Million | 887.48 Million | 670.31 Million | 610.63 Million | 489.44 Million |
| Cost of Revenue | 412.74 Million | 408 Million | 370.27 Million | 252.75 Million | 186.25 Million | 141.21 Million |
| Gross Profit | 568.08 Million | 566.28 Million | 517.21 Million | 417.55 Million | 424.37 Million | 348.23 Million |
| Operating Expenses | 433.22 Million | 441.55 Million | 407.14 Million | 322.95 Million | 343.17 Million | 291.54 Million |
| Selling, General and Administrative Expenses | 380.19 Million | 379.06 Million | 349.82 Million | 277.33 Million | 294.8 Million | 253.51 Million |
| Research and Development Expenses | 20.25 Million | 18.23 Million | 14.02 Million | 12.97 Million | 13.07 Million | 8.29 Million |
| Other Expenses | -737.72 Thousand | 44.26 Million | 43.29 Million | 32.64 Million | 35.28 Million | 9.15 Million |
| Cost and Expenses | 845.96 Million | 849.56 Million | 777.41 Million | 575.7 Million | 529.42 Million | 432.76 Million |
| Operating Income | 134.85 Million | 123.02 Million | 112.52 Million | 94.97 Million | 86.35 Million | 66.16 Million |
| Interest Expense | 6.22 Million | 13.91 Million | 3.49 Million | 2.84 Million | 111.75 Thousand | 67.58 Thousand |
| Income Tax Expense | 17.7 Million | 16.03 Million | 14.47 Million | 13.4 Million | 11.77 Million | 10.63 Million |
| Earnings before Tax | 129.24 Million | 119.17 Million | 109.02 Million | 94.49 Million | 83.55 Million | 75.31 Million |
| Net Income | 110.43 Million | 101.16 Million | 93.16 Million | 79.11 Million | 71.77 Million | 64.68 Million |
| Earnings Per Share Basic | 1.15 | 1.18 | 1.09 | 0.92 | 0.83 | 0.75 |
| Earnings Per Share Diluted | 1.13 | 1.17 | 1.09 | 0.92 | 0.83 | 0.75 |
| Weighted Average Shares Outstanding | 96.02 Million | 85.54 Million | 85.54 Million | 85.99 Million | 86.67 Million | 86.24 Million |
| Weighted Average Shares Outstanding (Diluted) | 97.72 Million | 93.38 Million | 85.54 Million | 85.99 Million | 86.67 Million | 86.24 Million |
| Gross Margin | 0.58 | 0.58 | 0.58 | 0.62 | 0.69 | 0.71 |
| EBIT Margin | 0.17 | 0.16 | 0.15 | 0.17 | 0.16 | 0.18 |
| Profit Margin | 0.11 | 0.10 | 0.10 | 0.12 | 0.12 | 0.13 |
| EBITDA | 166.4 Million | 150.88 Million | 129.37 Million | 112.02 Million | 96.86 Million | 87.21 Million |
| Earnings Before Tax Margin | 0.14 | 0.13 | 0.13 | 0.14 | 0.14 | 0.14 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 261.56 Million | 245.24 Million | 210.11 Million | 264.59 Million | 980.82 Million | 216.21 Million |
| Cost of Revenue | 103.01 Million | 91.07 Million | 79.96 Million | 113.43 Million | 412.74 Million | 73.42 Million |
| Gross Profit | 158.54 Million | 154.16 Million | 130.15 Million | 151.15 Million | 568.08 Million | 142.79 Million |
| Operating Expenses | 130.43 Million | 123.97 Million | 104.29 Million | 118.78 Million | 442.77 Million | 110.37 Million |
| Selling, General and Administrative Expenses | 154.39 Million | 93.97 Million | 100.25 Million | 72.02 Million | - | 123.84 Million |
| Research and Development Expenses | 9.59 Million | 10.53 Million | 3.71 Million | 4.51 Million | - | 5.12 Million |
| Other Expenses | -33.55 Million | -134.33 Thousand | 4.97 Million | -5.26 Million | -5.61 Million | -486.68 Thousand |
| Cost and Expenses | 233.45 Million | 215.05 Million | 184.25 Million | 232.22 Million | 855.52 Million | 183.79 Million |
| Operating Income | 35.2 Million | 32.16 Million | 30.66 Million | 36.87 Million | 134.85 Million | 34.92 Million |
| Interest Expense | 928.84 Thousand | 908.41 Thousand | 802.1 Thousand | 1 Million | 6.11 Million | 1.3 Million |
| Income Tax Expense | 4.06 Million | 3.65 Million | 4.57 Million | 4.57 Million | 17.7 Million | 4.79 Million |
| Earnings before Tax | 33.9 Million | 32.03 Million | 35.63 Million | 31.6 Million | 129.24 Million | 34.44 Million |
| Net Income | 29.91 Million | 28.5 Million | 31.14 Million | 26.32 Million | 110.43 Million | 29.84 Million |
| Earnings Per Share Basic | 0.29 | 0.28 | 0.30 | 0.57 | - | 0.28 |
| Earnings Per Share Diluted | 0.29 | 0.28 | 0.30 | 0.55 | - | 0.28 |
| Weighted Average Shares Outstanding | 104.78 Million | 103.82 Million | 103.82 Million | 98.51 Million | 96.02 Million | 105.15 Million |
| Weighted Average Shares Outstanding (Diluted) | 104.78 Million | 103.82 Million | 103.82 Million | 101.91 Million | 97.72 Million | 105.15 Million |
| Gross Margin | 0.61 | 0.63 | 0.62 | 0.57 | 0.58 | 0.66 |
| EBIT Margin | 0.13 | 0.15 | 0.18 | 0.12 | - | 0.17 |
| Profit Margin | 0.11 | 0.12 | 0.15 | 0.10 | 0.11 | 0.14 |
| EBITDA | 34.83 Million | 36.13 Million | 38.78 Million | 32.58 Million | - | 36.12 Million |
| Earnings Before Tax Margin | 0.13 | 0.13 | 0.15 | 0.14 | 0.14 | 0.16 |
IFGLEXPOR
IPXAF
AFN
FFN-PA
002860
EQB